RumbleOn Announces Strategic Partnership with Sonic Automotive

RumbleOn’s First Partnership within the Automotive Industry   Provides Sonic Automotive Customers at More than 100 Dealerships with Instant Values and Enhanced Liquidity Options CHARLOTTE, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) -- RumbleOn, Inc. (Nasdaq:RMBL), a disruptive e-commerce platform that facilitates the ability of consumers and dealers to buy, sell, trade, and … [Read more...]

ShiftPixy, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Results

IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ShiftPixy, Inc. (NASDAQ:PIXY), a developing, proprietary next-gen technology platform for workforce engagement and management, today announced operating results for the fiscal fourth quarter and year ended August 31, 2017. 2017 Fiscal Fourth Quarter Highlights Gross billings grew over 20% to $33.1 million for the fourth … [Read more...]

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Equity lock-up and standstill arrangement between the companies to expire on 31 December 2017 Mechelen, Belgium; 14 December 2017; 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the decision to opt-in on the co-promotion of filgotinib with collaboration partner Gilead Sciences in eight European countries, should filgotinib be approved for commercial … [Read more...]

Acer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

NEWTON, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the closing of the previously announced underwritten public offering of 916,667 shares of its common … [Read more...]

Global Blood Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced an agreement to sell $100.0 million in shares of its common … [Read more...]